[Production of hyper-immune serum for diagnosis of herpes virus hominis infections].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to A Sauerbrei.
Explore the source record for details and available documents.
A new technique for the detection of Herpesvirus hominis (HVH) in materials from patients, based on mixed haemadsorption with Ehrlich mouse ascites tumour cells, was proposed. Investigations on 100 pustule punctates and smears from 75 patients with typical clinical signs of various primary and recurrent infections yielded positive results in 80% of cases. This was in good accordance with HVH isolations in various cell cultures. The new technique can, therefore, be recommended for routine diagnosis. Its main advantage is the rapid virus diagnosis.
In 34 patients without pre-existing infection of the urinary tract mostly a few days after insertion of an indwelling catheter a bacteriuria with 10(5) germs per ml urine developed. In 24 patients from the moment of the first proof of bacteriuria up to the removal of the catheter 1 to 10 days passed away. During this time in 6 patients a cylindruria, in no case, however, an antibody-coat of the bacteria could be established. In 10 patients who carried the catheter for a longer time, the excretion of antibody-coated germs in the urine began 11 to 18 days after the first proof of bacteriuria. A cylindruria was observed in 9 of these patients. Altogether the proof of cylinders in the early phase of the renal infection was more sensitive than that of antibody-coated bacteria in the urine. The probability of a provable participation of the kidneys in catheter-conditioned infections of the urinary tract consequently increases with increasing period of indwelling of the catheter.
Povidone-iodine (PVP-I) is a broad-spectrum microbicide with in vitro activity against bacteria, viruses, fungi and protozoans. A 5% solution of PVP-I proved to be highly effective in ophthalmic surgery for the prophylaxis of endophthalmitis. For the antiseptic treatment of eye infections a novel application form of PVP-I has been developed by using a PVP-I liposome complex which demonstrated an excellent antimicrobial efficacy. In this study it could be shown that the novel liposomal formulations containing 2.5 or 5% PVP-I were as active as the aqueous solution against herpes simplex virus type 1, adenovirus type 8, coxsackievirus A9 and Chlamydia trachomatis in cell culture referring to equal PVP-I concentrations. Long-term cytotoxicity experiments demonstrated a moderate cytotoxicity for both formulations with a better tolerability of the liposomal PVP-I formulation compared with the aqueous solution. There is no evidence for a genotoxic activity of these agents.